Octopath AI Raises GBP 1.5M Seed

Octopath AI, based in the United Kingdom, is a spinout from the UCL Department of Medical Physics and Biomedical Engineering that specializes in artificial intelligence tools for cancer pathology. The company recently launched with GBP 1.5 million in total funding, consisting of a seed investment round and a grant.

Investors

The funding was led by TwinPath Ventures, with additional funding provided by an Innovate UK Growth Catalyst grant.

Octopath AI Use of Funds

The capital will be used to support clinical evaluation and regulatory work required to secure approval for the company's AI-powered diagnostic platform.

About Octopath AI

Founded in 2026 by Dr. Esther Bar, Dr. Zhuoyan Shen, and Dr. Charles-Antoine Collins Fekete, Octopath AI develops foundation models for tissue slide analysis. Its platform includes tools like Kraken for cell classification and Nemo for immunohistochemistry analysis, aiming to provide single-cell resolution for cancer diagnostics.

Funding Details

Company Website: https://octopath.ai

Company: Octopath AI
Raised: GBP 1.5M
Round: Seed
Funding Date: November 3, 2026
Lead Investor: TwinPath Ventures
Additional Investors: Innovate UK
Software Category: Healthcare AI
Source: https://allsci.com/news/corporate-strategy/ai-cancer-pathology-octopath-launches-with-15m-to/